Table 1.
Set I | Set II | |||||
---|---|---|---|---|---|---|
Lesional | Non-lesional | Lesional | ||||
Protein name | PsA:PsC FC ** | P-value *** | PsA:PsC FC | P-value | PsA:PsC FC | P-value |
CPN2 | 17.4 | <0.001 | 2.4 | 0.030 | 1.9 | 0.032 |
GPS1 | 6.0 | 0.014 | 1.2 | 0.385 | 17.9 | 0.008 |
C16ORF62 | 6.0 | <0.001 | 5.3 | 0.007 | 3.9 | 0.667 |
FHL1 | 4.6 | <0.001 | 3.1 | 0.021 | 2.2 | 0.016 |
SRPX | 3.8 | 0.043 | 3.3 | 0.014 | 5.0 | 0.008 |
SNCA | 3.6 | <0.001 | 1.7 | 0.089 | 3.8 | 0.095 |
POSTN | 3.5 | 0.001 | 2.8 | 0.013 | 7.5 | 0.032 |
PAFAH1B2 | 3.3 | 0.004 | 2.0 | 0.104 | 0.8 | 0.667 |
SRP14 | 3.0 | 0.019 | 1.3 | 0.570 | 2.4 | 0.016 |
ITGB5 | 2.7 | 0.006 | 3.5 | 0.017 | 4.2 | 0.032 |
PPP2R4 | 2.2 | 0.043 | 2.0 | 0.678 | 3.9 | 0.008 |
LZIC | 2.0 | 0.036 | 1.6 | 0.212 | 1.2 | 0.413 |
*The description of Set I and Set II are given in the experimental methods section.
**Fold change (FC) represents the ratio of means of 10 (Set I) or 5 (Set II) skin samples per group. Data are based on normalized XIC ratios, as described in the experimental methods section. PsA, psoriatic arthritis; PsC, cutaneous psoriasis.
***P-Values were calculated using the non-parametric Mann-Whitney U test.